294 related articles for article (PubMed ID: 32561853)
1. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract][Full Text] [Related]
2. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
3. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
4. P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model.
Batisse-Lignier M; Sahut-Barnola I; Tissier F; Dumontet T; Mathieu M; Drelon C; Pointud JC; Damon-Soubeyrand C; Marceau G; Kemeny JL; Bertherat J; Tauveron I; Val P; Martinez A; Lefrançois-Martinez AM
Oncogene; 2017 Aug; 36(31):4445-4456. PubMed ID: 28368424
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
6. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
7. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
[TBL] [Abstract][Full Text] [Related]
8. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
[TBL] [Abstract][Full Text] [Related]
9. Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process.
He H; Dai J; Yang X; Wang X; Sun F; Zhu Y
Biol Chem; 2018 May; 399(6):593-602. PubMed ID: 29730647
[TBL] [Abstract][Full Text] [Related]
10. Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.
Simon DP; Hammer GD
Mol Cell Endocrinol; 2012 Mar; 351(1):2-11. PubMed ID: 22266195
[TBL] [Abstract][Full Text] [Related]
11. The genetics of adrenocortical tumors.
Espiard S; Bertherat J
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):311-34. PubMed ID: 26038203
[TBL] [Abstract][Full Text] [Related]
12. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
13. RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
Liu-Chittenden Y; Jain M; Gaskins K; Wang S; Merino MJ; Kotian S; Kumar Gara S; Davis S; Zhang L; Kebebew E
Oncogene; 2017 Jun; 36(25):3541-3552. PubMed ID: 28114280
[TBL] [Abstract][Full Text] [Related]
14. AXIN genetic analysis in adrenocortical carcinomas updated.
Guimier A; Ragazzon B; Assié G; Tissier F; Dousset B; Bertherat J; Gaujoux S
J Endocrinol Invest; 2013 Dec; 36(11):1000-3. PubMed ID: 23812285
[TBL] [Abstract][Full Text] [Related]
15. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.
Heaton JH; Wood MA; Kim AC; Lima LO; Barlaskar FM; Almeida MQ; Fragoso MC; Kuick R; Lerario AM; Simon DP; Soares IC; Starnes E; Thomas DG; Latronico AC; Giordano TJ; Hammer GD
Am J Pathol; 2012 Sep; 181(3):1017-33. PubMed ID: 22800756
[TBL] [Abstract][Full Text] [Related]
16. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
17. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
[TBL] [Abstract][Full Text] [Related]
18. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression.
Drelon C; Berthon A; Mathieu M; Ragazzon B; Kuick R; Tabbal H; Septier A; Rodriguez S; Batisse-Lignier M; Sahut-Barnola I; Dumontet T; Pointud JC; Lefrançois-Martinez AM; Baron S; Giordano TJ; Bertherat J; Martinez A; Val P
Hum Mol Genet; 2016 Jul; 25(13):2789-2800. PubMed ID: 27149985
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
20. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]